Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders

Kazuo Tamura, Akio Urabe, Minoru Yoshida, Akihisa Kanamaru, Yoshihisa Kodera, Shinichiro Okamoto, Shigefumi Maesaki, Tohru Masaoka

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The study was conducted as a prospective multicenter trial to evaluate the efficacy and safety of micafungin in patients with invasive fungal infections (IFIs) in hematological disorders. A total of 277 patients was registered, and 197 were assessed for clinical efficacy. The mean dosage and duration of micafungin were 170.7 mg/day and 22.0 days, respectively. The efficacy rates were 87.5% (7/8) for patients with candidiasis, 44.7% (17/38) for probable IFIs, 61.9% (39/63) for possible IFIs and 80.7% (71/88) for those who failed to respond to antibacterials. In patients with febrile neutropenia (below 500 μL), despite broad-spectrum antibacterial treatment over 2 days, 86.3% (44/ 51) of patients had a favourable response to micafungin. The incidence of adverse events related to micafungin was 14.1% (39/277), but most of them were mild and reversible. These data indicate the usefulness of micafungin as a novel therapeutic drug for both empirical and targeted therapy for IFIs.

Original languageEnglish
Pages (from-to)92-100
Number of pages9
JournalLeukemia and Lymphoma
Volume50
Issue number1
DOIs
Publication statusPublished - 2009

Fingerprint

Echinocandins
Antifungal Agents
Safety
Febrile Neutropenia
Candidiasis
Multicenter Studies
Therapeutics
micafungin
Invasive Fungal Infections
Incidence
Pharmaceutical Preparations

Keywords

  • Echinocandin
  • Empirical therapy
  • Febrile neutropenia
  • Fungal infection
  • Hematological disorders
  • Micafungin

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. / Tamura, Kazuo; Urabe, Akio; Yoshida, Minoru; Kanamaru, Akihisa; Kodera, Yoshihisa; Okamoto, Shinichiro; Maesaki, Shigefumi; Masaoka, Tohru.

In: Leukemia and Lymphoma, Vol. 50, No. 1, 2009, p. 92-100.

Research output: Contribution to journalArticle

Tamura, Kazuo ; Urabe, Akio ; Yoshida, Minoru ; Kanamaru, Akihisa ; Kodera, Yoshihisa ; Okamoto, Shinichiro ; Maesaki, Shigefumi ; Masaoka, Tohru. / Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. In: Leukemia and Lymphoma. 2009 ; Vol. 50, No. 1. pp. 92-100.
@article{aa49846100e44754981573ad3e4c6859,
title = "Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders",
abstract = "The study was conducted as a prospective multicenter trial to evaluate the efficacy and safety of micafungin in patients with invasive fungal infections (IFIs) in hematological disorders. A total of 277 patients was registered, and 197 were assessed for clinical efficacy. The mean dosage and duration of micafungin were 170.7 mg/day and 22.0 days, respectively. The efficacy rates were 87.5{\%} (7/8) for patients with candidiasis, 44.7{\%} (17/38) for probable IFIs, 61.9{\%} (39/63) for possible IFIs and 80.7{\%} (71/88) for those who failed to respond to antibacterials. In patients with febrile neutropenia (below 500 μL), despite broad-spectrum antibacterial treatment over 2 days, 86.3{\%} (44/ 51) of patients had a favourable response to micafungin. The incidence of adverse events related to micafungin was 14.1{\%} (39/277), but most of them were mild and reversible. These data indicate the usefulness of micafungin as a novel therapeutic drug for both empirical and targeted therapy for IFIs.",
keywords = "Echinocandin, Empirical therapy, Febrile neutropenia, Fungal infection, Hematological disorders, Micafungin",
author = "Kazuo Tamura and Akio Urabe and Minoru Yoshida and Akihisa Kanamaru and Yoshihisa Kodera and Shinichiro Okamoto and Shigefumi Maesaki and Tohru Masaoka",
year = "2009",
doi = "10.1080/10428190802635500",
language = "English",
volume = "50",
pages = "92--100",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders

AU - Tamura, Kazuo

AU - Urabe, Akio

AU - Yoshida, Minoru

AU - Kanamaru, Akihisa

AU - Kodera, Yoshihisa

AU - Okamoto, Shinichiro

AU - Maesaki, Shigefumi

AU - Masaoka, Tohru

PY - 2009

Y1 - 2009

N2 - The study was conducted as a prospective multicenter trial to evaluate the efficacy and safety of micafungin in patients with invasive fungal infections (IFIs) in hematological disorders. A total of 277 patients was registered, and 197 were assessed for clinical efficacy. The mean dosage and duration of micafungin were 170.7 mg/day and 22.0 days, respectively. The efficacy rates were 87.5% (7/8) for patients with candidiasis, 44.7% (17/38) for probable IFIs, 61.9% (39/63) for possible IFIs and 80.7% (71/88) for those who failed to respond to antibacterials. In patients with febrile neutropenia (below 500 μL), despite broad-spectrum antibacterial treatment over 2 days, 86.3% (44/ 51) of patients had a favourable response to micafungin. The incidence of adverse events related to micafungin was 14.1% (39/277), but most of them were mild and reversible. These data indicate the usefulness of micafungin as a novel therapeutic drug for both empirical and targeted therapy for IFIs.

AB - The study was conducted as a prospective multicenter trial to evaluate the efficacy and safety of micafungin in patients with invasive fungal infections (IFIs) in hematological disorders. A total of 277 patients was registered, and 197 were assessed for clinical efficacy. The mean dosage and duration of micafungin were 170.7 mg/day and 22.0 days, respectively. The efficacy rates were 87.5% (7/8) for patients with candidiasis, 44.7% (17/38) for probable IFIs, 61.9% (39/63) for possible IFIs and 80.7% (71/88) for those who failed to respond to antibacterials. In patients with febrile neutropenia (below 500 μL), despite broad-spectrum antibacterial treatment over 2 days, 86.3% (44/ 51) of patients had a favourable response to micafungin. The incidence of adverse events related to micafungin was 14.1% (39/277), but most of them were mild and reversible. These data indicate the usefulness of micafungin as a novel therapeutic drug for both empirical and targeted therapy for IFIs.

KW - Echinocandin

KW - Empirical therapy

KW - Febrile neutropenia

KW - Fungal infection

KW - Hematological disorders

KW - Micafungin

UR - http://www.scopus.com/inward/record.url?scp=59249099656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59249099656&partnerID=8YFLogxK

U2 - 10.1080/10428190802635500

DO - 10.1080/10428190802635500

M3 - Article

C2 - 19172498

AN - SCOPUS:59249099656

VL - 50

SP - 92

EP - 100

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -